Increased CCL18 expression in patients with cutaneous T‐cell lymphoma: association with disease severity and prognosis
- 9 March 2012
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 27 (1), e60-e67
- https://doi.org/10.1111/j.1468-3083.2012.04495.x
Abstract
Background CC chemokine ligand (CCL) 18 is expressed by monocytes and dendritic cells (DCs), and has potent chemotactic activity for T cells, B cells and DCs. CCL18 expression is up‐regulated in lesional skin of atopic dermatitis and bullous pemphigoid, suggesting its important roles in the development of these skin diseases. Objective To investigate roles of CCL18 in cutaneous T‐cell lymphoma (CTCL). Methods The CCL18 messenger RNA (mRNA) expression in CTCL skin (n = 21) and in normal skin (n = 7) was examined by quantitative RT‐PCR. CCL18 expression was also examined by immunohistochemistry. Serum CCL18 levels were measured in 38 patients with CTCL and 20 healthy controls by enzyme‐linked immunosorbent assay. We also analysed correlation between serum CCL18 levels and other clinical and laboratory data. Results The CTCL lesional skin contained higher levels of CCL18 mRNA than normal skin. CCL18 was expressed by dermal macrophages and DCs in CTCL skin. Serum CCL18 levels in patients with CTCL were significantly higher than those of healthy controls and correlated with types of skin lesions. They also significantly correlated with modified severity‐weighted assessment scores, serum sIL‐2R, LDH, IL‐4, IL‐10, IL‐31, CCL17 and CCL26 levels. Patients with high serum levels of CCL18 showed significantly poor prognosis compared with those with low CCL18 levels. Conclusion CCL18 mRNA is up‐regulated in CTCL lesional skin, and serum CCL18 levels are significantly increased and correlated with the severity of CTCL. These results suggest that CCL18 may be associated with the development of CTCL.Keywords
This publication has 52 references indexed in Scilit:
- Up-Regulation of the Chemokine CCL18 by Macrophages Is a Potential Immunomodulatory Pathway in Cutaneous T-Cell LymphomaThe American Journal of Pathology, 2011
- Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerJournal of Clinical Oncology, 2011
- CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3Cancer Cell, 2011
- Tumor-Associated Macrophages and Survival in Classic Hodgkin's LymphomaNew England Journal of Medicine, 2010
- Enhanced interleukin‐10 production by dendritic cells upon stimulation with Toll‐like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretionScandinavian Journal of Rheumatology, 2009
- A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoidesJournal of the American Academy of Dermatology, 2006
- Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processesJournal of Leukocyte Biology, 2005
- Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activityJournal of Allergy and Clinical Immunology, 2001
- Influence of Alternatively and Classically Activated Macrophages on Fibrogenic Activities of Human FibroblastsCellular Immunology, 2000
- Bullous pemphigoid: A cause of peripheral blood eosinophiliaJournal of the American Academy of Dermatology, 1983